Diffuse oesophageal involvement in anti-NXP2 myositis and response to combined immunosuppressive therapy

Rheumatology (Oxford). 2021 Nov 3;60(11):e378-e380. doi: 10.1093/rheumatology/keab422.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenosine Triphosphatases / immunology*
  • Aged
  • Antibodies, Antinuclear / blood
  • Antirheumatic Agents / administration & dosage
  • Autoantibodies / blood
  • Calcinosis / etiology
  • Calcinosis / pathology
  • DNA-Binding Proteins / immunology*
  • Deglutition Disorders / diagnosis
  • Deglutition Disorders / etiology
  • Esophagus* / diagnostic imaging
  • Esophagus* / pathology
  • Esophagus* / physiopathology
  • Female
  • Gastrostomy / methods
  • Glucocorticoids / administration & dosage*
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage*
  • Immunosuppression Therapy / methods
  • Magnetic Resonance Imaging / methods
  • Myositis* / diagnosis
  • Myositis* / immunology
  • Myositis* / physiopathology
  • Myositis* / therapy
  • Rituximab / administration & dosage*
  • Tomography, X-Ray Computed / methods
  • Tracheostomy / methods
  • Treatment Outcome

Substances

  • Antibodies, Antinuclear
  • Antirheumatic Agents
  • Autoantibodies
  • DNA-Binding Proteins
  • Glucocorticoids
  • Immunoglobulins, Intravenous
  • Rituximab
  • Adenosine Triphosphatases
  • MORC3 protein, human